Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.
NCT ID: NCT06276127
Last Updated: 2025-03-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-04-30
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
INTRODUCTION: The study focuses on comparing the effectiveness of oral Bisoprolol, a beta-1 adrenergic receptor blocker, against intravenous Diltiazem, a calcium channel blocker, in treating rapid atrial fibrillation or flutter with rapid ventricular response in an emergency setting. This research aims to fill the gap in empirical evidence regarding the use of oral Bisoprolol for these conditions, potentially offering a convenient, evidence-based alternative for patient management in emergency departments where established protocols are lacking.
METHOD: This study is a randomized controlled trial targeting patients who present to the emergency room with symptomatic atrial fibrillation or flutter and rapid ventricular response requiring intervention. Participants will be split into two groups and undergo continuous monitoring of vital signs and regular electrocardiograms to ensure safety and document any adverse effects. The primary focus is on patient safety while evaluating the efficacy of the treatments.
AIM: Evaluate the efficacy and safety of oral bisoprolol in treating atrial fibrillation or atrial flutter with rapid ventricular response in an emergency department setting.
PRIMARY OJECTIVES: The primary efficacy outcome will be evaluated by achieving a HR\<110 beats per minute or a decrease ≥20% of baseline HR at 60 minutes. The primary safety outcome measures are HR \< 60 bpm and SBP \< 95 mm Hg.
SECONDARY OBJECTIVES: The use of Rescue medication, proportion of patients who required hospitalization, worsening of heart failure or pulmonary oedema, side effect of medication ( dizziness, headaches, gastrointestinal symptoms)
PATEINT POPULATION: Adults (18 and older) presenting to the emergency department at Sultan Qaboos University Hospital with symptomatic atrial fibrillation or atrial flutter with rapid ventricular response requiring treatment.
INTERVENTION: A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg) or a single intravenous dose of Diltiazem at 0.25 mg/kg (to a maximum dose of 30 mg).
CLINICAL MEASURMENT: Heart rate recorded every 15 minutes up to the 90-minute mark, with a 12-lead ECG performed every 30 minutes.
OUTCOME: For therapy to be considered effective, patients must achieve a ventricular rate ≤110/min or experience a drop-in ventricular rate of at least 20% at 60 minutes.
METHOD: This study is a randomized controlled trial targeting patients who present to the emergency room with symptomatic atrial fibrillation or flutter and rapid ventricular response requiring intervention. Participants will be split into two groups and undergo continuous monitoring of vital signs and regular electrocardiograms to ensure safety and document any adverse effects. The primary focus is on patient safety while evaluating the efficacy of the treatments.
AIM: Evaluate the efficacy and safety of oral bisoprolol in treating atrial fibrillation or atrial flutter with rapid ventricular response in an emergency department setting.
PRIMARY OJECTIVES: The primary efficacy outcome will be evaluated by achieving a HR\<110 beats per minute or a decrease ≥20% of baseline HR at 60 minutes. The primary safety outcome measures are HR \< 60 bpm and SBP \< 95 mm Hg.
SECONDARY OBJECTIVES: The use of Rescue medication, proportion of patients who required hospitalization, worsening of heart failure or pulmonary oedema, side effect of medication ( dizziness, headaches, gastrointestinal symptoms)
PATEINT POPULATION: Adults (18 and older) presenting to the emergency department at Sultan Qaboos University Hospital with symptomatic atrial fibrillation or atrial flutter with rapid ventricular response requiring treatment.
INTERVENTION: A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg) or a single intravenous dose of Diltiazem at 0.25 mg/kg (to a maximum dose of 30 mg).
CLINICAL MEASURMENT: Heart rate recorded every 15 minutes up to the 90-minute mark, with a 12-lead ECG performed every 30 minutes.
OUTCOME: For therapy to be considered effective, patients must achieve a ventricular rate ≤110/min or experience a drop-in ventricular rate of at least 20% at 60 minutes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
NCT01914926
Heart Rate and Rhythm Disorders
COMPLETED
PHASE4
Effect of Diltiazem on Pharmacokinetics of BMS-914392
NCT01211808
Atrial Fibrillation
COMPLETED
PHASE1
Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter
NCT04141553
Atrial Fibrillation
Atrial Flutter
Rapid Ventricular Response
UNKNOWN
PHASE4
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
NCT03472495
Atrial Fibrillation and Flutter
COMPLETED
PHASE4
Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation
NCT02832089
Atrial Fibrillation
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
= Aim of the Study: This open-label randomized controlled trial (RCT) aims to assess the effectiveness and safety of oral bisoprolol in treating atrial fibrillation (AF) with rapid ventricular response (RVR) and atrial flutter within an acute ED setting. We aim to determine the viability of utilizing oral bisoprolol as a primary treatment option for atrial fibrillation with rapid ventricular response (RVR) and atrial flutter by evaluating its clinical outcomes, focusing on rate control and potential adverse effects, and comparing them with those of intravenous diltiazem. The findings from this research will enhance our understanding and guide clinicians towards evidence-based therapeutic decisions, ensuring optimal patient care and improved outcomes.
= Research Objectives and Hypothesis: The research aims to test the null hypothesis, which posits that there is no significant difference in achieving a heart rate (HR) below 110 beats/min or a reduction in ventricular rate by at least 20% between the oral bisoprolol (PO) and intravenous diltiazem (IV) groups after 60 minutes.
= Study Design: This is a prospective, open-label, randomized controlled trial that will be conducted as a single-center investigation within the Emergency Department of Sultan Qaboos University Hospital (SQUH). This study will involve adult patients aged 18 and older, and all eligible participants will be given written informed consent to join the research.
= Control Group: Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
= Intervention Group: Participants in this group will receive a single oral dose of bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
* Primary Endpoints:
* The primary efficacy outcome evaluated by achieving a HR \< 110 beats per minute or a decrease ≥20% of baseline HR at 60 minutes.
* The primary safety outcome measures were HR \< 60 bpm and SBP \< 95 mm Hg.
* Secondary Endpoints:
* The use of rescue medication (Rescue rate control defined as the administration of a supplementary rate control medication after 60 minutes of the initial dose of the interventional drug).
* Proportion of patients who required hospitalization (hospital admission/ICU admission).
* ED revisit.
* Treatment-related adverse events.
* Dizziness, headaches, gastrointestinal symptoms.
* Worsening of heart failure or pulmonary edema.
* Sample Size:
In addressing the novel concept of comparing the effectiveness of oral bisoprolol versus IV diltiazem in treating AF or atrial flutter with RVR in an acute setting, we aim to conduct a pilot study with 30 patients in each group to calculate the study sample size.
* Study Procedures:
1. Present to the Clinical Site:
* An eligible adult patient aged 18 years or older, who presents with symptomatic rapid ventricular response atrial fibrillation or atrial flutter and requires treatment for rate control.
2. Eligibility Assessments:
* Inclusion and exclusion criteria will be checked.
3. Informed Consent:
* Potentially eligible participants will be identified by their treating clinicians. Written informed consent to participate in this study will follow a process of information exchange between clinicians and potential participants.
4. Study the Effectiveness in Achieving Rate Control:
* Data will be collected prospectively, including demographics, medical history, vital signs, and ECG results. Each patient will be promptly assessed, and continuous monitoring will be established for every patient to monitor cardiac rhythm, heart rate (HR), blood pressure, and oxygen saturation levels.
* Heart rate will be recorded every 15 mins till the 90-minute mark.
* For the therapy to be considered effective, the patients had to achieve a ventricular rate ≤110/min or experience a drop in ventricular rate of at least 20% at 60 minutes.
* 12-lead ECG will be done every 30 minutes at 0, 30, and 60 minutes.
* Relevant secondary outcomes will be recorded.
5. Standard-of-Care Procedures:
* Patients may receive additional medications as part of their emergency department treatment after 60 minutes if they remain hemodynamically stable. Any additional medications administered will be recorded. The need for additional medications (including the drug administered, the dose, the time, and the route of administration) will be recorded.
6. Safety Assessments:
* All adverse events will be documented on the adverse event case log. Serious adverse events should be immediately reported to the primary investigator. Any serious adverse event will be reported immediately to the Institutional Review Board. An adverse event is considered serious if it causes a threat to the patient's life or functioning. The U.S. Food and Drug Administration (FDA) defines a serious adverse event (SAE) as any untoward medical occurrence that:
* Results in death.
* Is life-threatening (places the patient at risk of death).
* Requires hospitalization or prolongs an existing hospitalization.
* Causes persistent or significant disability or incapacity.
* Requires medical intervention to prevent one of the above outcomes.
7. Follow-Up:
* All participants will be followed up after 24 hours and 48 hours.
* Risks and Benefits:
Bisoprolol, a cardioselective beta-1 adrenergic agent, is recognized for its potency and the convenience of once-daily dosing. It is well-tolerated and deemed suitable for patients with chronic bronchoconstrictive disease, with safety established through clinical trials. On the other hand, diltiazem, a calcium channel blocker, is commonly used for hypertension and short-term AF management due to its rapid onset and lower impact on blood pressure, making it suitable for emergencies.
In collaboration with cardiology experts, the designated 60-minute time frame has been established to balance clinical relevance with patient safety. The administration of oral bisoprolol is considered a reliable and convenient treatment modality, assumed to be fast, painless, and associated with a lower risk of complications. This approach aims to facilitate a smooth transition to oral maintenance and provide an alternative for AF management in a busy Emergency Department. Meanwhile, intravenous (IV) diltiazem is acknowledged for its rapid onset, rendering it effective for the treatment of symptomatic atrial fibrillation patients in the emergency department. Throughout the ED phase, each patient will undergo close monitoring to ensure their utmost safety.
It is crucial to carefully consider the balance between potential benefits and risks, particularly in cases involving heart failure patients. Detailed monitoring protocols are in place to swiftly detect and manage any adverse effects or complications that may arise. Our preemptive strategies include comprehensive and regular patient monitoring, the implementation of an emergency protocol to address unexpected issues, and a meticulous medication review prior to any treatment administration. We are committed to transparent and ongoing communication with all study participants, maintaining a continuous focus on safeguarding their health and ensuring that the potential advantages of participation outweigh the risks.
= Research Objectives and Hypothesis: The research aims to test the null hypothesis, which posits that there is no significant difference in achieving a heart rate (HR) below 110 beats/min or a reduction in ventricular rate by at least 20% between the oral bisoprolol (PO) and intravenous diltiazem (IV) groups after 60 minutes.
= Study Design: This is a prospective, open-label, randomized controlled trial that will be conducted as a single-center investigation within the Emergency Department of Sultan Qaboos University Hospital (SQUH). This study will involve adult patients aged 18 and older, and all eligible participants will be given written informed consent to join the research.
= Control Group: Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
= Intervention Group: Participants in this group will receive a single oral dose of bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
* Primary Endpoints:
* The primary efficacy outcome evaluated by achieving a HR \< 110 beats per minute or a decrease ≥20% of baseline HR at 60 minutes.
* The primary safety outcome measures were HR \< 60 bpm and SBP \< 95 mm Hg.
* Secondary Endpoints:
* The use of rescue medication (Rescue rate control defined as the administration of a supplementary rate control medication after 60 minutes of the initial dose of the interventional drug).
* Proportion of patients who required hospitalization (hospital admission/ICU admission).
* ED revisit.
* Treatment-related adverse events.
* Dizziness, headaches, gastrointestinal symptoms.
* Worsening of heart failure or pulmonary edema.
* Sample Size:
In addressing the novel concept of comparing the effectiveness of oral bisoprolol versus IV diltiazem in treating AF or atrial flutter with RVR in an acute setting, we aim to conduct a pilot study with 30 patients in each group to calculate the study sample size.
* Study Procedures:
1. Present to the Clinical Site:
* An eligible adult patient aged 18 years or older, who presents with symptomatic rapid ventricular response atrial fibrillation or atrial flutter and requires treatment for rate control.
2. Eligibility Assessments:
* Inclusion and exclusion criteria will be checked.
3. Informed Consent:
* Potentially eligible participants will be identified by their treating clinicians. Written informed consent to participate in this study will follow a process of information exchange between clinicians and potential participants.
4. Study the Effectiveness in Achieving Rate Control:
* Data will be collected prospectively, including demographics, medical history, vital signs, and ECG results. Each patient will be promptly assessed, and continuous monitoring will be established for every patient to monitor cardiac rhythm, heart rate (HR), blood pressure, and oxygen saturation levels.
* Heart rate will be recorded every 15 mins till the 90-minute mark.
* For the therapy to be considered effective, the patients had to achieve a ventricular rate ≤110/min or experience a drop in ventricular rate of at least 20% at 60 minutes.
* 12-lead ECG will be done every 30 minutes at 0, 30, and 60 minutes.
* Relevant secondary outcomes will be recorded.
5. Standard-of-Care Procedures:
* Patients may receive additional medications as part of their emergency department treatment after 60 minutes if they remain hemodynamically stable. Any additional medications administered will be recorded. The need for additional medications (including the drug administered, the dose, the time, and the route of administration) will be recorded.
6. Safety Assessments:
* All adverse events will be documented on the adverse event case log. Serious adverse events should be immediately reported to the primary investigator. Any serious adverse event will be reported immediately to the Institutional Review Board. An adverse event is considered serious if it causes a threat to the patient's life or functioning. The U.S. Food and Drug Administration (FDA) defines a serious adverse event (SAE) as any untoward medical occurrence that:
* Results in death.
* Is life-threatening (places the patient at risk of death).
* Requires hospitalization or prolongs an existing hospitalization.
* Causes persistent or significant disability or incapacity.
* Requires medical intervention to prevent one of the above outcomes.
7. Follow-Up:
* All participants will be followed up after 24 hours and 48 hours.
* Risks and Benefits:
Bisoprolol, a cardioselective beta-1 adrenergic agent, is recognized for its potency and the convenience of once-daily dosing. It is well-tolerated and deemed suitable for patients with chronic bronchoconstrictive disease, with safety established through clinical trials. On the other hand, diltiazem, a calcium channel blocker, is commonly used for hypertension and short-term AF management due to its rapid onset and lower impact on blood pressure, making it suitable for emergencies.
In collaboration with cardiology experts, the designated 60-minute time frame has been established to balance clinical relevance with patient safety. The administration of oral bisoprolol is considered a reliable and convenient treatment modality, assumed to be fast, painless, and associated with a lower risk of complications. This approach aims to facilitate a smooth transition to oral maintenance and provide an alternative for AF management in a busy Emergency Department. Meanwhile, intravenous (IV) diltiazem is acknowledged for its rapid onset, rendering it effective for the treatment of symptomatic atrial fibrillation patients in the emergency department. Throughout the ED phase, each patient will undergo close monitoring to ensure their utmost safety.
It is crucial to carefully consider the balance between potential benefits and risks, particularly in cases involving heart failure patients. Detailed monitoring protocols are in place to swiftly detect and manage any adverse effects or complications that may arise. Our preemptive strategies include comprehensive and regular patient monitoring, the implementation of an emergency protocol to address unexpected issues, and a meticulous medication review prior to any treatment administration. We are committed to transparent and ongoing communication with all study participants, maintaining a continuous focus on safeguarding their health and ensuring that the potential advantages of participation outweigh the risks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atrial Fibrillation With Rapid Ventricular Response
Atrial Flutter With Rapid Ventricular Response
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Study Design: Open-label, randomized controlled trial.
Participants: Patients with atrial fibrillation/flutter and rapid ventricular rate.
Treatment Arms: Oral Bisoprolol vs. Intravenous Diltiazem.
Randomization: Subjects randomly assigned to either treatment group.
Primary Endpoint: Reduction of heart rate to a target level within a specific timeframe.
Secondary Outcomes: Adverse effects, hospital admission rates, additional rate control needs.
Objective: Compare effectiveness and safety of oral Bisoprolol to intravenous Diltiazem.
Monitoring: Continuous observation of vital signs and electrocardiograms for safety.
Participants: Patients with atrial fibrillation/flutter and rapid ventricular rate.
Treatment Arms: Oral Bisoprolol vs. Intravenous Diltiazem.
Randomization: Subjects randomly assigned to either treatment group.
Primary Endpoint: Reduction of heart rate to a target level within a specific timeframe.
Secondary Outcomes: Adverse effects, hospital admission rates, additional rate control needs.
Objective: Compare effectiveness and safety of oral Bisoprolol to intravenous Diltiazem.
Monitoring: Continuous observation of vital signs and electrocardiograms for safety.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
While the treating physician, nurse, and the patient will not be blinded to the treatment, the statistician analyzing it will remain blinded to treatment allocations.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Bisoprolol
A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg)
Group Type
EXPERIMENTAL
Oral Bisoprolol
Intervention Type
DRUG
Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
Intravenous Diltiazem
single intravenous dose of Diltiazem at 0.25 mg/kg (to a maximum dose of 30 mg)
Group Type
OTHER
Intravenous Diltiazem
Intervention Type
DRUG
Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Bisoprolol
Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
Intervention Type
DRUG
Intravenous Diltiazem
Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Bisoprolol hemifumarate
Diltiazem nondihydropyridine calcium channel blocker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years old.
* Atrial fibrillation (RVR) or Atrial flutter on electrocardiogram.
* Heart rate \>120 beats/min
* Stable patient with stable vital signs (Defined as having a SBP \>110 mmHg, oxygen saturation \> 94% on room air or with a simple face mask, a respiratory rate within normal limits, being conscious and oriented, and not having any concurrent life-threatening conditions such as myocardial infarction (MI) or Class IV heart failure).
* Mentally competent patient who can understand and sign the consent form.
* Atrial fibrillation (RVR) or Atrial flutter on electrocardiogram.
* Heart rate \>120 beats/min
* Stable patient with stable vital signs (Defined as having a SBP \>110 mmHg, oxygen saturation \> 94% on room air or with a simple face mask, a respiratory rate within normal limits, being conscious and oriented, and not having any concurrent life-threatening conditions such as myocardial infarction (MI) or Class IV heart failure).
* Mentally competent patient who can understand and sign the consent form.
Exclusion Criteria
* Acute myocardial infarction.
* Known congenital and acquired valvular defects.
* Pre-excitation syndromes.
* Ventricular rate \> 220beats/min.
* Administration of AV nodal blocking agents within the previous 24 h (beta blockers, non-dihydropyridine calcium channel blockers, digoxin and amiodarone or receiving regular maintains oral dose).
* Allergy to either bisoprolol or diltiazem.
* Severe hepatic and renal failure.
* Pregnancy / breastfeeding.
* A history of cocaine or methamphetamine use within 24 hours before arrival.
* Known Asthmatic.
* Known congenital and acquired valvular defects.
* Pre-excitation syndromes.
* Ventricular rate \> 220beats/min.
* Administration of AV nodal blocking agents within the previous 24 h (beta blockers, non-dihydropyridine calcium channel blockers, digoxin and amiodarone or receiving regular maintains oral dose).
* Allergy to either bisoprolol or diltiazem.
* Severe hepatic and renal failure.
* Pregnancy / breastfeeding.
* A history of cocaine or methamphetamine use within 24 hours before arrival.
* Known Asthmatic.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oman Medical Speciality Board
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatin Khalfan Alomairi
Resident, Emergency Medicine, OMSB
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usama Al Khalasi, MD
Role: STUDY_CHAIR
The Medical City for Military & Security Services, Oman
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sultan Qaboos University Hospital
Muscat, Al-khod, Oman
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Oman
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, Marshall J. Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department. J Emerg Med. 2015 Aug;49(2):175-82. doi: 10.1016/j.jemermed.2015.01.014. Epub 2015 Apr 22.
Reference Type
BACKGROUND
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. No abstract available.
Reference Type
BACKGROUND
Posen A, Bursua A, Petzel R. DOsing Strategy Effectiveness of Diltiazem in Atrial Fibrillation With Rapid Ventricular Response. Ann Emerg Med. 2023 Mar;81(3):288-296. doi: 10.1016/j.annemergmed.2022.08.462. Epub 2022 Nov 17.
Reference Type
BACKGROUND
Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, Rathod S, Grant S, Thomas E, Wyse DG. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011 Nov 1;58(19):1975-85. doi: 10.1016/j.jacc.2011.07.036.
Reference Type
BACKGROUND
Groenveld HF, Crijns HJ, Tijssen JG, Alings M, Hillege HL, Tuininga YS, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Rate control in atrial fibrillation, insight into the RACE II study. Neth Heart J. 2013 Apr;21(4):199-204. doi: 10.1007/s12471-013-0391-1. No abstract available.
Reference Type
BACKGROUND
Bakheit AH, Ali R, Alshahrani AD, El-Azab AS. Bisoprolol: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2021;46:51-89. doi: 10.1016/bs.podrm.2020.07.006. Epub 2020 Sep 8.
Reference Type
BACKGROUND
clinical_evaluation_of_bisoprolol_in_the_treatment.31.
Reference Type
BACKGROUND
Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, Yusu S, Yoshino H. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. doi: 10.1536/ihj.49.281.
Reference Type
BACKGROUND
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994 Oct;90(4):1765-73. doi: 10.1161/01.cir.90.4.1765.
Reference Type
BACKGROUND
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)-.
Reference Type
BACKGROUND
Demircan C, Cikriklar HI, Engindeniz Z, Cebicci H, Atar N, Guler V, Unlu EO, Ozdemir B. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005 Jun;22(6):411-4. doi: 10.1136/emj.2003.012047.
Reference Type
BACKGROUND
Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. Am J Emerg Med. 2022 Aug;58:39-42. doi: 10.1016/j.ajem.2022.03.058. Epub 2022 Apr 6.
Reference Type
BACKGROUND
Nicholson J, Czosnowski Q, Flack T, Pang PS, Billups K. Hemodynamic comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation rate control. Am J Emerg Med. 2020 Sep;38(9):1879-1883. doi: 10.1016/j.ajem.2020.06.034. Epub 2020 Jun 21.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://emedicine.medscape.com/article/151210-overview
Lawrence Rosenthal MPFFP of MDS of CP and ED of EFPD of CDU of MMMC. Atrial Flutter.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MERC301123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
NCT05391893
COMPLETED
PHASE4
Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm
NCT01266681
UNKNOWN
NA
Value of Heart Rate Lowering Therapy in Acute Myocarditis
NCT06312891
RECRUITING
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879
UNKNOWN
PHASE4
Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing
NCT01868880
WITHDRAWN
PHASE4
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
NCT01522651
COMPLETED
PHASE2
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
NCT00391846
COMPLETED
PHASE4
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
NCT03508271
COMPLETED
Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation
NCT01070667
UNKNOWN
PHASE4
Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
NCT01135017
TERMINATED
PHASE4
Rapid Atrial Fibrillation Treatment Strategy
NCT04092621
UNKNOWN
PHASE4
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
NCT00252187
COMPLETED
PHASE1/PHASE2
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
NCT00288730
COMPLETED
PHASE3
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
NCT01691313
COMPLETED
PHASE2
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
NCT06556732
RECRUITING
PHASE1
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
NCT06453577
ACTIVE_NOT_RECRUITING
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
NCT03026088
TERMINATED
PHASE4
Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation
NCT01527279
COMPLETED
PHASE4
Evaluation of Safety and Effectiveness on Oral Anticoagulants
NCT03765242
COMPLETED
Determination of Drug Levels for Pharmacotherapy of Heart Failure
NCT06035978
NOT_YET_RECRUITING
PHASE4
Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
NCT02046044
UNKNOWN
PHASE4
Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome
NCT05536271
COMPLETED
PHASE2
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
NCT03087487
COMPLETED
Safety Study of Tecadenoson to Treat Atrial Fibrillation
NCT00713401
COMPLETED
PHASE2
Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response
NCT05691959
UNKNOWN
PHASE2